Novo Nordisk cut sickle cell crises by 27%. Could etavopivat become its next major medicine?
Novo Nordisk seeks FDA and EMA approval for etavopivat after Phase 3 success. See what the results mean for sickle cell treatment.
Pharma & Biotech